Compare WGO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | JANX |
|---|---|---|
| Founded | 1958 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.8M | 984.3M |
| IPO Year | 1994 | 2021 |
| Metric | WGO | JANX |
|---|---|---|
| Price | $30.83 | $15.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $42.78 | ★ $47.00 |
| AVG Volume (30 Days) | 812.5K | ★ 1.3M |
| Earning Date | 03-25-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 106.82 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $1,985,674,000.00 | $10,000,000.00 |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | $34.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.80 | $12.12 |
| 52 Week High | $50.16 | $35.34 |
| Indicator | WGO | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 48.06 |
| Support Level | $29.38 | $13.13 |
| Resistance Level | $31.35 | $15.49 |
| Average True Range (ATR) | 1.15 | 0.61 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 67.53 | 4.80 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.